The Phase 3 OlympiA study examined the use of adjuvant olaparib in patients with high-risk, HER2-negative BC with a genetic BRCA1/2 mutation who had undergone either adjuvant or neoadjuvant chemotherapy. This evidence concerns the gene BRCA1 and breast cancer.